文献速递皮肤感染

VT-1161口服片治疗趾甲远端侧位甲下甲真菌病的II期随机双盲安慰剂对照剂量探索研究

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail.
PubMed 文献 · Br J Dermatol · 2020-07-13

该II期随机双盲安慰剂对照多中心研究纳入259例18-70岁、甲板真菌感染面积25-75%的趾甲远端侧位甲下甲真菌病患者,评估四种VT-1161口服方案与安慰剂的安全性和有效性。

要点

  • VT-1161口服治疗趾甲甲真菌病第48周完全治愈率32%-42%,安慰剂组0%。
  • VT-1161耐受性良好,未发现肝功能或QT间期不良影响。
  • 该药对慢性难治性甲真菌病显示潜力,需更大规模研究验证。

核心结论

  • VT-1161治疗趾甲远端侧位甲下甲真菌病可获得较高的甲清除率且安全性良好,值得进一步大规模研究。

研究设计与样本

  • II期随机双盲安慰剂对照多中心研究(NCT02267356),纳入259例18-70岁、甲板真菌感染面积25-75%的趾甲远端侧位甲下甲真菌病患者。
  • 患者随机分入五个治疗组:300 mg或600 mg VT-1161先每日给药2周,随后每周一次给药10周或22周,另设匹配安慰剂组;所有治疗结束后随访36周无治疗期。

主要发现

  • VT-1161耐受性良好,未发现对肝功能或QT间期的不良影响。

关键数值与推荐

  • 入组标准:年龄18-70岁,甲板真菌感染面积25-75%。

临床怎么用

  • VT-1161可作为趾甲远端侧位甲下甲真菌病的潜在口服治疗选择,但需更大规模研究确认后应用于临床。

局限性

  • 本研究为II期剂量探索研究,样本量有限,结论需更大规模研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Onychomycosis is a fungal disease that affects the fingernails and toenails and is predominantly caused by dermatophytes. VT-1161 is a novel inhibitor of fungal CYP51 through the inhibition of lanosterol demethylase, and has demonstrated potent activity against Trichophyton rubrum and Trichophyton mentagrophytes. OBJECTIVES: To evaluate the safety and efficacy of four dosing regimens of orally administered VT-1161 compared with placebo in patients with moderate-to-severe distal and lateral subungual onychomycosis of the toenail. METHODS: This was a phase II, randomized, double-blind, placebo-controlled, multicentre study (ClinicalTrials.gov identifier NCT02267356). Patients aged 18-70 years (n = 259) who had 25-75% mycotic involvement were randomized to five treatment groups. They received 300 mg VT-1161 as a 2-week daily dose, followed by a once-weekly dose for either 10 or 22 weeks, or 600 mg VT-1161 as a 2-week daily dose, followed by a once-weekly dose for either 10 or 22 weeks. All treatments were followed by a nontreatment period of 36 weeks. A matching placebo arm was included. RESULTS: In the intent-to-treat population, at week 48 the complete cure rates were 0% in the placebo group and ranged from 32% to 42% in the VT-1161 treatment groups (P < 0·001 vs. placebo). VT-1161 was well tolerated, with no evidence of an adverse effect on liver function or QT intervals. CONCLUSIONS: VT-1161 treatment led to high nail clearance rates and a favourable safety profile. VT-1161 exhibits characteristics that appear promising for the treatment of this chronic and difficult-to-treat condition and warrants further evaluation in larger studies.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Elewski B, Brand S, Degenhardt T, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. Br J Dermatol. 2020. PMID: 32421854. doi:10.1111/bjd.19224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。